2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation

Cited by (1,000)

Items 101–200 of 1,000

1. Impact of frailty models on the prescription of oral anticoagulants and on the incidence of stroke, bleeding, and mortality in older patients with atrial fibrillation: a systematic review
   Roberto Presta, Enrico Brunetti, Maria Cristina Polidori, Mario Bo · 2022 · Ageing Research Reviews
2. The impact of ABCB1, CYP3A4/5 and ABCG2 gene polymorphisms on rivaroxaban trough concentrations and bleeding events in patients with non-valvular atrial fibrillation
   Tingting Wu, Shuyi Wu, Li Li, Jing Xiang, Na Wang, Wenjun Chen, Jinhua Zhang · 2023 · Human Genomics
3. Renal decline in patients with non-valvular atrial fibrillation treated with rivaroxaban or warfarin: A population-based study from the United Kingdom
   Antonio González Pérez, Yanina Balabanova, María Eugenia Sáez, Gunnar Brobert, Luis Alberto García Rodríguez · 2022 · International Journal of Cardiology
4. Interactions Between Direct Oral Anticoagulants (DOACs) and Antiseizure Medications: Potential Implications on DOAC Treatment
   Rachel Goldstein, Aviya R. Jacobs, Lana Zighan, Naomi Gronich, Meir Bialer, Mordechai Muszkat · 2023 · CNS Drugs
5. Impact of Direct Oral Anticoagulant Concentration on Clinical Outcomes in Asian Patients with Atrial Fibrillation
   Shin‐Yi Lin, Sung‐Chun Tang, Ching‐Hua Kuo, Li‐Ting Ho, Yen‐Bin Liu, Yu‐Fong Peng, Li‐Kai Tsai, Chih‐Fen Huang, Jiann‐Shing Jeng · 2023 · Clinical Pharmacology & Therapeutics
6. Antioxidant Properties of Oral Antithrombotic Therapies in Atherosclerotic Disease and Atrial Fibrillation
   Luigi Falco, Viviana Tessitore, Giovanni Ciccarelli, Marco Malvezzi Caracciolo D’Aquino, Antonello D’Andrea, Egidio Imbalzano, Paolo Golino, Vincenzo Russo · 2023 · Antioxidants
7. Impact of P‐glycoprotein and/or CYP3A4‐interacting drugs on effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A meta‐analysis
   Maxim Grymonprez, Kevin Vanspranghe, Andreas Capiau, Koen Boussery, Stéphane Steurbaut, Lies Lahousse · 2022 · British Journal of Clinical Pharmacology
8. Diagnosis and Management of Cardiovascular Risk in Patients with Polycythemia Vera
   Giulia Benevolo, Monia Marchetti, Remo Melchio, Eloise Beggiato, Chiara Sartori, Carloalberto Biolè, Davide Rapezzi, Benedetto Bruno, Alberto Milan · 2023 · Vascular Health and Risk Management
9. Cardiovascular and non‐renal complications of chronic kidney disease: Managing risk
   Peter R Rossing, Tine W. Hansen, Thomas Kümler · 2024 · Diabetes Obesity and Metabolism
10. Management of patients with atrial tachycardia: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), the Latin American Heart Rhythm Society (LAHRS), and the Association for European Paediatric and Congenital Cardiology (AEPC)
    Ch. Meyer, Ann‐Kathrin Kahle, Nikolaos Dagres, Nicolas Derval, Thomas A. Dewland, Fabrizio Drago, Lars Eckardt, Antonio Frontera, Edward P. Gerstenfeld, Carina Abigail Hardy et al. · 2025 · EP Europace
11. Gender-differences in antithrombotic therapy across the spectrum of ischemic heart disease: Time to tackle the Yentl syndrome?
    Renzo Laborante, Josip A. Borovac, Mattía Galli, Daniele Rodolico, Giuseppe Ciliberti, Attilio Restivo, Luigi Cappannoli, Alessandra Arcudi, Rocco Vergallo, Andrea Zito et al. · 2022 · Frontiers in Cardiovascular Medicine
12. The extent of cytochrome P450 3A induction by antiseizure medications: A systematic review and network meta‐analysis
    Hagar Cohen, Ghadeer Mahajna, Tomer Ben‐Shushan, Ilan Matok, Sara Eyal · 2023 · Epilepsia
13. Apixaban Use in Patients with Kidney Impairment: A Review of Pharmacokinetic, Interventional, and Observational Study Data
    Stephen R. Mandt, Noble Thadathil, Christian Klem, Cristina Russ, Patricia L. McNamee, Kevin Stigge, Dong Cheng · 2024 · American Journal of Cardiovascular Drugs
14. Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians
    Tatjana Potpara, Bogdan Marković, Marek Grygier, Simonetta Genovesi, Apostolos Tzikas, Serge Bovéda, Jens Erik Nielsen‐Kudsk, Giuseppe Boriani, Gregory Y.H. Lip, A. John Camm · 2025 · EP Europace
15. Frailty and oral anticoagulant prescription in adults with atrial fibrillation: A systematic review
    Mary Bul, Fahad Shaikh, Julee McDonagh, Caleb Ferguson · 2022 · Aging Medicine
16. Pharmacokinetics and Dosing Regimens of Direct Oral Anticoagulants in Morbidly Obese Patients: An Updated Literature Review
    Ying Jiao Zhao, Mingxing Guo, Dandan Li, Wanyi Xu, Chen Pan, Chaoran He, Xiangli Cui · 2023 · Clinical and Applied Thrombosis/Hemostasis
17. Impact of Cerebral Microbleeds in Stroke Patients with Atrial Fibrillation
    Yannie O. Y. Soo, Annaelle Zietz, Brian Yiu, Vincent Mok, Alexandros A. Polymeris, David Julian Seiffge, Gareth Ambler, Duncan Wilson, Thomas Wai Hong Leung, Suk Fung Tsang et al. · 2023 · Annals of Neurology
18. Perioperative Management of Antithrombotic Therapy in Patients Who Undergo Dental Procedures: A Systematic Review of the Literature and Network Meta-Analysis
    Andrea Boccatonda, Alessio Frisone, Felice Lorusso, Calogero Bugea, Maristella Di Carmine, Cosima Schiavone, Giulio Cocco, Damiano D’Ardes, Antônio Scarano, Maria Teresa Guagnano · 2023 · International Journal of Environmental Research and Public Health
19. Efficacy and Safety of Direct Oral Anticoagulants versus Warfarin in Obese Patients (BMI ≥ 30 kg/m2) with Atrial Fibrillation or Venous Thromboembolism: An Updated Systematic Review and Meta-Analysis
    Paschalis Karakasis, Nikolaos Ktenopoulos, Konstantinos Pamporis, Μarios Sagris, Στέργιος Σουλαϊδόπουλος, Maria Gerogianni, Ioannis Leontsinis, George A. Giannakoulas, Dimitris Tousoulis, Nikolaos Fragakis et al. · 2024 · Journal of Clinical Medicine
20. Pharmacokinetic and Pharmacodynamic Interactions between Food or Herbal Products and Oral Anticoagulants: Evidence Review, Practical Recommendations, and Knowledge Gaps
    Azita H. Talasaz, Bridget McGonagle, Mohsen Hajiqasemi, Zahra Alimohammad Ghelichkhan, Parham Sadeghipour, Sina Rashedi, Adam C. Cuker, Tara Lech, Samuel Zachary Goldhaber, Douglas L. Jennings et al. · 2024 · Seminars in Thrombosis and Hemostasis
21. Population pharmacokinetic and pharmacodynamic analysis of rivaroxaban in Chinese patients with non-valvular atrial fibrillation
    Xiaoqin Liu, Yufei Zhang, Hong-yan Ding, Ming‐Ming Yan, Zheng Jiao, Ming-kang Zhong, Chun-Lai Ma · 2022 · Acta Pharmacologica Sinica
22. Concomitant Use of Diltiazem With Direct Oral Anticoagulants and Bleeding Risk in Atrial Fibrillation
    Yunwen Xu, Alex R. Chang, Lesley A. Inker, Mara McAdams‐DeMarco, Morgan Erika Grams, Jung‐Im Shin · 2022 · Journal of the American Heart Association
23. Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events
    Emily K. Acton, Sean Hennessy, Michael A. Gelfand, Charles E. Leonard, Warren B. Bilker, Di Shu, Allison Wright Willis, Scott Eric Kasner · 2024 · JAMA Neurology
24. Treating cancer-associated venous thromboembolism: A practical approach
    Eric Van Cutsem, Isabelle Mahé, Enriqueta Felip, Giancarlo Agnelli, Ahmad Hussein Awada, Alexander T. Cohen, Anna Falanga, Mario Mandalà, Marc Peeters, Nikolaos Tsoukalas et al. · 2024 · European Journal of Cancer
25. Prediction of Post-Discharge Bleeding in Elderly Patients with Acute Coronary Syndromes: Insights from the BleeMACS Registry
    Alberto Garay, Francesç Formiga, Sergio Raposeiras‐Roubín, Emad Abu-Assi, José Carlos Sánchez‐Salado, Victòria Lorente, Oriol Alegre, Josè P.S. Henriques, Fabrizio D’Ascenzo, Jorge Saucedo et al. · 2018 · Thrombosis and Haemostasis
26. The Interplay Between Obesity and Venous Thromboembolism: From Molecular Aspects to Clinical Issue
    Patrycja Sandra Zawadzka, Anna M. Imiela, Piotr Pruszczyk · 2025 · International Journal of Molecular Sciences
27. Comprehensive geriatric assessment in elderly and senile patients with cardiovascular diseases. Expert opinion of the Russian Association of Gerontologists and Geriatricians
    О. Н. Ткачева, Yu. V. Kotovskaya, Н. К. Рунихина, Elena V Frolova, A. S. Milto, L. A. Aleksanyan, E. A. Tyukhmenev, Anna Yu. Shchedrina, А. В. Розанов, Остапенко Валентина Сергеевна et al. · 2021 · Kardiologiia
28. Management of DOAC in Patients Undergoing Planned Surgery or Invasive Procedure: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) Position Paper
    Alessandro Squizzato, Daniela Poli, Doris Barcellona, Antonio Ciampa, Elvira Grandone, Cesare Manotti, Marco Moia, Vincenzo Toschi, Alberto Tosetto, Sophie Testa et al. · 2021 · Thrombosis and Haemostasis
29. Carbamazepine, phenytoin, and oral anticoagulants: Drug‐drug interaction and clinical events in a retrospective cohort
    Matteo Candeloro, John W. Eikelboom, Noel Chan, Vinai C. Bhagirath, James Demetrios Douketis, Sam Schulman · 2022 · Research and Practice in Thrombosis and Haemostasis
30. Effectiveness and Safety of Oral Anticoagulants in Cardiac Amyloidosis: Lights and Shadows
    Daniela Di Lisi, Leandro Di Caccamo, Giuseppe Damerino, Maria Cristina Portelli, Francesco Comparato, Vincenzo Di Stefano, Filippo Brighina, Egle Corrado, Alfredo Ruggero Galassi, Giuseppina Novo · 2022 · Current Problems in Cardiology
31. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care
    Paulus F. Kirchhof, Ladislav Pecen, Ameet Bakhai, Carlo de Asmundis, Joris R. de Groot, Jean‐Claude Deharo, Peter J. Kelly, Pierre Lévy, Esteban López de Sá, Pedro F. Monteiro et al. · 2022 · European Heart Journal - Cardiovascular Pharmacotherapy
32. Insights into the Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Older Adults with Atrial Fibrillation: A Structured Narrative Review
    Angela Elma Edwina, Nada Dia, Erwin Dreesen, Thomas Vanassche, Peter B. Verhamme, Isabel Spriet, Lorenz Roger Van der Linden, Jos Tournoy · 2023 · Clinical Pharmacokinetics
33. Comparing the risk of dementia in subjects with atrial fibrillation using non-vitamin K antagonist oral anticoagulants versus vitamin K antagonists: a Belgian nationwide cohort study
    Maxim Grymonprez, Mirko Petrović, Tine LM de Backer, M. Arfan Ikram, Stéphane Steurbaut, Lies Lahousse · 2023 · Age and Ageing
34. Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials
    John W. Eikelboom, Jeffrey Ian Weitz · 2023 · Journal of Thrombosis and Haemostasis
35. Clinical Outcomes in Metabolically Healthy and Unhealthy Obese and Overweight Patients With Atrial Fibrillation: Findings From the GLORIA-AF Registry
    Bernadette Corica, Giulio Francesco Romiti, Marco Proietti, Davide Antonio Mei, Giuseppe Boriani, Tze‐Fan Chao, Brian Olshansky, Menno Volkert Huisman, Gregory Y.H. Lip · 2023 · Mayo Clinic Proceedings
36. Levetiracetam Interaction with Direct Oral Anticoagulants: A Pharmacovigilance Study
    Mohammed Abou Kaoud, Ran Nissan, Amitai Segev, Avi Sabbag, David Orion, Elad Maor · 2023 · CNS Drugs
37. Bleeding in acute coronary syndrome: from definitions, incidence, and prognosis to prevention and management
    Claudio Laudani, Davide Capodanno, Dominick Joseph Angiolillo · 2023 · Expert Opinion on Drug Safety
38. Stroke Prevention in Atrial Fibrillation: Our Current Failures and Required Research
    M. Edip Gurol, Clinton B. Wright, Scott Janis, Eric Edward Smith, Elif Gökçal, Vivek Yerrapu Reddy, José G. Merino, Jonathan Chong Hsu · 2023 · Stroke
39. Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone
    Nicola Potere, Matteo Candeloro, Ettore Porreca, Stefano Marinari, Camilla Federici, Raffaella Auciello, Marcello Di Nisio · 2021 · Journal of Thrombosis and Thrombolysis
40. Clinical and subclinical acute brain injury caused by invasive cardiovascular procedures
    Radosław Lenarczyk, Marco Proietti, Jan Friedrich Scheitz, Dipen Shah, Eberhard Siebert, Diana Adrienne Gorog, Jacek P. Kowalczyk, Nikolaos E. Bonaros, George Ntaios, Wolfram Doehner et al. · 2024 · Nature Reviews Cardiology
41. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration
    Haini Wen, Qingfeng He, Xiaoqiang Xiang, Zheng Jiao, Jian‐Guang Yu · 2022 · Thrombosis Research
42. Management of oral anticoagulant therapy after intracranial hemorrhage in patients with atrial fibrillation
    Fabiana Lucà, Furio Colivicchi, Fabrizio Giovanni Oliva, Maurizio Giuseppe Abrignani, Giorgio Caretta, Stefania Angela Di Fusco, Simona Giubilato, Stefano Cornara, Concetta Di Nora, Andrea Pozzi et al. · 2023 · Frontiers in Cardiovascular Medicine
43. Prescription of DOACs in Patients with Atrial Fibrillation at Different Stages of Renal Insufficiency
    Kai M. Hahn, Mathias Lamparter · 2023 · Advances in Therapy
44. Ultrasound-Guided Venous Axillary Access Versus Standard Fluoroscopic Technique for Cardiac Lead Implantation
    Francesco Vitali, Michele Malagù, Nicola Bianchi, Martina De Raffele, Marco Manfrini, Federico Gibiino, Alberto Boccadoro, Giorgia Azzolini, Cristina Balla, Matteo Bertini · 2024 · JACC. Clinical electrophysiology
45. Oral anticoagulation in patients with left ventricular thrombus: a systematic review and meta-analysis
    Paul Michael Haller, Niema Kazem, Stefan Agewall, Claudio Borghi, Claudio Ceconi, Dobromir Dobrev, Elisabetta Cerbai, Erik Lerkevang Grove, Juan Carlos Kaski, Basil S. Lewis et al. · 2024 · European Heart Journal - Cardiovascular Pharmacotherapy
46. The value and limitations of new oral anticoagulant plasma level assessments
    Lorenz Roger Van der Linden, Julie Hias, Thomas Vanassche · 2022 · European Heart Journal Supplements
47. Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study
    Konsta Teppo, Jussi Jaakkola, Juhani K.E. Airaksinen, Fausto Biancari, Olli Halminen, Jukka Putaala A, Pirjo E. Mustonen, Jari K. Haukka, Juha E.K. Hartikainen, Alex Luojus et al. · 2022 · Journal of the American Heart Association
48. Evolving data on cardiovascular complications in cancer
    Ruth A.L. Willems, Kristien Winckers, Charlotte Biesmans, Judith de Vos‐Geelen, Hugo Ten Cate · 2022 · Thrombosis Research
49. Assessing the proportion of the Danish population at risk of clinically significant drug-drug interactions with new oral antivirals for early treatment of COVID-19
    Carsten Schade Larsen · 2022 · International Journal of Infectious Diseases
50. Prevention, Diagnosis and Treatment of Thromboembolic Complications in Traumatology and Orthopedics: Methodological Guidelines
    Светлана Анатольевна Божкова, Тихилов Рашид Муртузалиевич, V. V. Andriyashkin, Il'dar Fuatovich Akhtyamov, Mikhail V. Belov, S. V. Dianov, Alina R. Kasimova, Каплунов Олег Анатольевич, S S Kopenkin, Dmitry A. Malanin et al. · 2022 · Traumatology and Orthopedics of Russia
51. Oral Anticoagulant Use and Appropriateness in Elderly Patients with Atrial Fibrillation in Complex Clinical Conditions: ACONVENIENCE Study
    Clara Bonanad, Francesç Formiga, Manuel P. Anguita, Roberto Petidier Torregrossa, Alejandra Gullón · 2022 · Journal of Clinical Medicine
52. The Effectiveness and Safety of Autologous Platelet Concentrates as Hemostatic Agents after Tooth Extraction in Patients on Anticoagulant Therapy: A Systematic Review of Randomized, Controlled Trials
    Maria Domenica Campana, Angelo Aliberti, Alfonso Acerra, Pasquale Sammartino, Pasquale Dolce, Gilberto Sammartino, Roberta Gasparro · 2023 · Journal of Clinical Medicine
53. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies
    Yi‐Hsin Chan, Chih-Yu Chan, Shao‐Wei Chen, Tze‐Fan Chao, Gregory Y.H. Lip · 2023 · EP Europace
54. Optimal management of cardiac surgery patients using direct oral anticoagulants: recommendations for clinical practice
    Samuel Heuts, Angelique Ceulemans, Gerhardus J.A.J.M. Kuiper, Jan‐Uwe Schreiber, Bernard J. van Varik, Renske H. Olie, Hugo Ten Cate, Jos G. Maessen, Milan Milojevic, Bart A. E. Maesen · 2023 · European Journal of Cardio-Thoracic Surgery
55. Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Decade of Experience
    Jocelyn R Spruit, Tim A.C. de Vries, Martin E.W. Hemels, Ron Pisters, Joris R. de Groot, R.W.M.M. Jansen · 2024 · Drugs & Aging
56. Anticoagulation in Atrial Fibrillation Cardioversion: What Is Crucial to Take into Account
    Fabiana Lucà, Simona Giubilato, Stefania Angela Di Fusco, Laura Piccioni, Carmelo Massimiliano Rao, Annamaria Iorio, Laura Cipolletta, Emilia D’Elia, Sandro Gelsomino, Roberta Rossini et al. · 2021 · Journal of Clinical Medicine
57. Oral Anticoagulant Use in Patients with Morbid Obesity: A Systematic Review and Meta-Analysis
    Tzu‐Fei Wang, Marc Carrier, Karine Fournier, Deborah M. Siegal, Grégoire Le Gal, Aurélien Delluc · 2021 · Thrombosis and Haemostasis
58. Can direct oral anticoagulants be used in kidney transplant recipients?
    Kathrine Parker, Janette Chu, Muir Morton, Shiv Bhutani, Michael L. Picton, Sandip Mitra, Jecko V. Thachil · 2021 · Clinical Transplantation
59. Stroke Prevention in Atrial Fibrillation
    Chern‐En Chiang, Tze‐Fan Chao, Eue‐Keun Choi, Toon Wei Lim, Rungroj Krittayaphong, Mingfang Li, Minglong Chen, Yutao Guo, Ken Okumura, Gregory Y.H. Lip · 2022 · JACC Asia
60. Direct oral anticoagulants (DOACs): From the laboratory point of view
    Sandra Margetić, Sandra Šupraha Goreta, Ivana Ćelap, Marija Razum · 2022 · Acta Pharmaceutica
61. Treatment of Persistent Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation on Adequate Oral Anticoagulation: Pathways of Care for All-comers and Heart Failure Patients
    Josip Katić, Josip A. Borovac · 2023 · Cardiac failure review
62. Direct oral anticoagulants for the treatment of splanchnic vein thrombosis: A state of art
    Giovanni Monaco, Luca Bucherini, Bernardo Stefanini, Fabio Piscaglia, Francesco Giuseppe Foschi, Luca Ielasi · 2023 · World Journal of Gastroenterology
63. Asymptomatic atrial fibrillation among hospitalized patients: clinical correlates and in-hospital outcomes in Improving Care for Cardiovascular Disease in China-Atrial Fibrillation
    Jing Lin, Xue-Ying Wu, Deyong Long, Chen-Xi Jiang, Caihua Sang, Ribo Tang, Songnan Li, Wei Wang, Xueyuan Guo, Man Ning et al. · 2023 · EP Europace
64. Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
    Robert Patrick Giugliano · 2022 · European Heart Journal Supplements
65. High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the ESC Working Group on Cardiovascular Surgery
    Andreas Schäfer, Mirvat A. Alasnag, Daniele Giacoppo, Carlos Adolfo Collet, Tanja K. Rudolph, Ariel Roguin, Piotr Paweł Buszman, Róisín Colleran, Giulio Giuseppe Stefanini, Thierry Lefèvre et al. · 2024 · EuroIntervention
66. Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases
    José Miguel Rivera‐Caravaca, Stephanie Lucy Harrison, Benjamin J. R. Buckley, Elnara Fazio‐Eynullayeva, Paula Underhill, Francisco R. Marín, Gregory Y.H. Lip · 2021 · Cardiovascular Diabetology
67. Eighty years of oral anticoagulation: Learning from history
    Maria Rosa Montinari, Sergio Minelli, Raffaele De Caterina · 2021 · Vascular Pharmacology
68. Trends in oral anticoagulant use in patients with atrial fibrillation in Belgium from 2013 to 2019: A nationwide cohort study
    Maxim Grymonprez, Tine LM de Backer, Andreas Capiau, Delphine Vauterin, Els Mehuys, Koen Boussery, Stéphane Steurbaut, Lies Lahousse · 2022 · British Journal of Clinical Pharmacology
69. Comparison of the real-life clinical outcomes of warfarin with effective time in therapeutic range and non-vitamin K antagonist oral anticoagulants: Insight from the AFTER-2 trial
    Adem Aktan, Tuncay Güzel, Burhan Aslan, Raif Kılıç, Serhat Günlü, Mehmet Özbek, Bayram Arslan, Muhammed Demir, Faruk Ertaş · 2023 · Kardiologia Polska
70. Management of bleeding in patients on direct oral anticoagulants in emergency department: where we are and where we are going
    Francesca De Marco, Gabriele Valli, Carlo Ancona, Maria Pia Ruggieri · 2023 · European Heart Journal Supplements
71. Genetic variants influenced the risk of bleeding and pharmacodynamics of rivaroxaban in patients with nonvalvular atrial fibrillation: A multicentre prospective cohort study
    Qian Xiang, Zhe Wang, Guangyan Mu, Qiufen Xie, Zhiyan Liu, Shuang Zhou, Hanxu Zhang, Zining Wang, Jie Jiang, Kun Hu et al. · 2023 · Clinical and Translational Medicine
72. Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis
    Riccardo Giossi, Danilo Menichelli, Federico D’Amico, Laura Idotta, Mario Cirino, Laura Scardoni, Costanza Furlanetto, Matteo Maggi, Ottavia Bernocchi, Federica Bosca et al. · 2023 · Journal of Thrombosis and Haemostasis
73. Renin‐angiotensin-aldosterone system inhibitors and mortality risk in elderly patients with atrial fibrillation. Insights from the nationwide START registry
    Danilo Menichelli, Daniela Poli, Emilia Antonucci, Gualtiero Palareti, Pasquale Pignatelli, Daniele Pastori · 2023 · European Journal of Internal Medicine
74. Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation
    Mette Søgaard, Anne Gulbech Ording, Flemming Skjøth, Torben Bjerregaard Larsen, Peter Brønnum Nielsen · 2023 · European Heart Journal - Cardiovascular Pharmacotherapy
75. Preoperative Assessment and Management of Cardiovascular Risk in Patients Undergoing Non-Cardiac Surgery: Implementing a Systematic Stepwise Approach during the COVID-19 Pandemic Era
    Eduardo Bossone, Filippo Cademartiri, Hani Alsergani, Salvatore Chianese, Rahul Mehta, Valentina Capone, Carlo Ruotolo, Imran H. Tarrar, Antonio Frangiosa, Olga Vriz et al. · 2021 · Journal of Cardiovascular Development and Disease
76. Early or late initiation of dabigatran versus vitamin-K-antagonists in acute ischemic stroke or TIA: The PRODAST study
    Gerrit Maximilian Große, Anika Hüsing, Andreas Stang, Nils Kuklik, Marcus Brinkmann, Darius G. Nabavi, Paul Sparenberg, Karin Weißenborn, Klaus Gröschel, Georg Royl et al. · 2023 · International Journal of Stroke
77. Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry
    Agnieszka Kapłon‐Cieślicka, Monika M. Gawalko, Mah B, Beata Uziębło‐Życzkowska, pk pkj, Katarzyna Starzyk, I G, Ludmiła Daniłowicz‐Szymanowicz, Dhirendra Singh, Maciej Wójcik et al. · 2022 · Journal of Clinical Medicine
78. Real-World Investigation on Anticoagulation Management Before and After Catheter Ablation for Atrial Fibrillation in Japan ― Periprocedural and Long-Term Outcomes ―
    Akihiko Nogami, Kyoko Soejima, Itsuro Morishima, Kenichi Hiroshima, Ritsushi Kato, Satoru Sakagami, Fumiharu Miura, Keisuke Okawa, Tetsuya Kimura, Takashi Inoue et al. · 2022 · Circulation Journal
79. Diagnostic and therapeutic pathways for the malignant left atrial appendage: European Heart Rhythm Association physician survey
    Ante Anić, Darija Baković, Zrinka Jurišić, Michał M. Farkowski, Lucija Lisica, Toni Brešković, Jens Erik Nielsen‐Kudsk, Laura Perrotta, Carlo de Asmundis, Serge Bovéda et al. · 2023 · EP Europace
80. Rivaroxaban vs Vitamin K Antagonist in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease
    Reinhold Hugo Kreutz, Gilbert Deray, Jürgen Floege, Marianne Gwechenberger, Kai Hahn, Andreas Rüdiger Luft, Pontus Börje Persson, Christoph Axthelm, Jürg Hans Beer, Jutta K Bergler-Klein et al. · 2024 · JACC Advances
81. Direct-Acting Oral Anticoagulants in patients at extremes of body weight: a review of pharmacological considerations and clinical implications
    Rosa Talerico, Roberto Pola, Frederikus Albertus Klok, Menno Volkert Huisman · 2024 · TH Open
82. Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease
    Yunwen Xu, Shoshana H. Ballew, Alex R. Chang, Lesley A. Inker, Morgan Erika Grams, Jung‐Im Shin · 2024 · Journal of the American Heart Association
83. Use of Direct Acting Oral Anticoagulants in Elderly Patients with Atrial Fibrillation: A Multicenter, Cross-Sectional Study in Spain
    Pablo Díez‐Villanueva, Juan Cosı́n-Sales, Vanessa Roldán, Vivencio Barrios, Diana Riba-Artés, Olga Gavín‐Sebastián · 2023 · Journal of Clinical Medicine
84. Mutant CYP3A4/5 Correlated with Clinical Outcomes by Affecting Rivaroxaban Pharmacokinetics and Pharmacodynamics in Patients with Atrial Fibrillation
    Xiaoye Li, Zhi‐Chun Gu, Zi Wang, Qing Xu, Chun-Lai Ma, Qianzhou Lv · 2023 · Cardiovascular Drugs and Therapy
85. Direct Oral Anticoagulants in Patients with Obesity and Atrial Fibrillation: Position Paper of Italian National Association of Hospital Cardiologists (ANMCO)
    David Mocini, Stefania Angela Di Fusco, Edoardo Mocini, Lorenzo M. Donini, Carlo Lavalle, Andrea Di Lenarda, Carmine Riccio, Pasquale Caldarola, Leonardo De Luca, Michele Massimo Gulizia et al. · 2021 · Journal of Clinical Medicine
86. Antithrombotic dilemmas in stroke medicine: new data, unsolved challenges
    Jonathan G. Best, Beatrix Cardus, Catharina J.M. Klijn, Gregory Y.H. Lip, David Julian Seiffge, Eric Edward Smith, David John Werring · 2022 · Journal of Neurology Neurosurgery & Psychiatry
87. Measuring Mobile Phone Application Usability for Anticoagulation from the Perspective of Patients, Caregivers, and Healthcare Professionals
    Shih‐Wei Wang, Chun-Chi Chiou, Chien-Hao Su, Cheng-Chih Wu, Shu-Chen Tsai, Tsu‐Kung Lin, Chien‐Ning Hsu · 2022 · International Journal of Environmental Research and Public Health
88. Oral anticoagulants: a systematic overview of reviews on efficacy and safety, genotyping, self-monitoring, and stakeholder experiences
    Claire Khouja, Ginny Brunton, Michelle Angela Richardson, Gillian Stokes, Laurence Blanchard, Helen Burchett, Meena Khatwa, Ruth Walker, Kath E. Wright, Amanda J. Sowden et al. · 2022 · Systematic Reviews
89. Drug–Drug Interactions in the Treatment of Cancer-Associated Venous Thromboembolism with Direct Oral Anticoagulants
    Maja Hellfritzsch, Jakob Nørgaard Henriksen, Marianne Ingerslev Holt, Erik Lerkevang Grove · 2023 · Seminars in Thrombosis and Hemostasis
90. Comparative safety and effectiveness of oral anticoagulants in patients with non-valvular atrial fibrillation and high risk of gastrointestinal bleeding: A nationwide French cohort study
    Gregory Y.H. Lip, Robert Benamouzig, Anne‐Céline Martin, Giancarlo Pesce, Gaëlle Gusto, Nadia Quignot, Artak Khachatryan, Feng Dai, Fouad Sedjelmaci, José Chaves et al. · 2024 · PLoS ONE
91. Feasibility and usability of a mobile health tool on anticoagulation management for patients with atrial fibrillation: a pilot study
    Chi Zhang, Mang-Mang Pan, Na Wang, Weiwei Wang, Zheng Li, Zhi‐Chun Gu, Hou‐Wen Lin · 2021 · European Journal of Clinical Pharmacology
92. Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC‐EHRA EURObservational research programme in atrial fibrillation general long‐term registry
    Vincenzo Livio Malavasi, Marco Vitolo, Marco Proietti, Igor Diemberger, Laurent Fauchier, Francisco R. Marín, Michael Näbauer, Tatjana Potpara, Gheorghe‐Andrei Dan, Zbigniew F. Kalarus et al. · 2022 · European Journal of Clinical Investigation
93. Use and Prescription of Direct Oral Anticoagulants in Older and Frail Patients with Atrial Fibrillation: A Multidisciplinary Consensus Document
    Marco Proietti, Marina Camera, Maurizio Alberto Gallieni, L. Gianturco, Antonio Gidaro, Carlo Piemontese, Giuseppe Pizzetti, Franco Redaelli, Barbara Scimeca, Carlo Sebastiano Tadeo et al. · 2022 · Journal of Personalized Medicine
94. Population Pharmacokinetic Models for Direct Oral Anticoagulants: A Systematic Review and Clinical Appraisal Using Exposure Simulation
    Jean E. Terrier, Frédéric Gaspar, Monia Guidi, Pierre Fontana, Youssef Daali, Chantal Csajka, Jean‐Luc Reny · 2022 · Clinical Pharmacology & Therapeutics
95. Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer
    Tzu‐Fei Wang · 2022 · Thrombosis Research
96. The conundrum of the complex relationship between acute kidney injury and cardiac arrhythmias
    Simonetta Genovesi, Giuseppe Regolisti, Alexandru Burlacu, Adrian Constantin Covic, Christian Combe, Sandip Mitra, Carlo Basile, The EuDial Working Group of ERA, Chiara Bartolucci · 2022 · Nephrology Dialysis Transplantation
97. UK prescribing practice of anticoagulants in patients with chronic kidney disease: a nephrology and haematology-based survey
    Kathrine Parker, Satarupa Choudhuri, Penny J Lewis, Jecko V. Thachil, Sandip Mitra · 2023 · BMC Nephrology
98. Stroke prevention in atrial fibrillation: A narrative review of current evidence and emerging strategies
    Amir Askarinejad, Deirdre A. Lane, Parham Sadeghipour, Majid Haghjoo, Gregory Y.H. Lip · 2025 · European Journal of Clinical Investigation
99. Atrial Fibrillation and Cancer: Pathophysiological Mechanism and Clinical Implications
    Alfredo Mauriello, Adriana Correra, Vincenzo Quagliariello, Martina Iovine, Pierpaolo Di Micco, Egidio Imbalzano, Francesco Giallauria, Antonio Giordano, Vincenzo Russo, Antonello D’Andrea et al. · 2025 · Journal of Clinical Medicine
100. Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents
     Luigi Spadafora, Federico Russo, Ewelina Bukowska‐Olech, Giorgia Panichella, Manuel Garofalo, Stefano Cacciatore, Pierre François Sabouret, Gianmarco Sarto, Beatrice Simeone, Erica Rocco et al. · 2025 · American Journal of Cardiovascular Drugs